Literature DB >> 8410146

Brain metastases of metastatic malignant melanoma: response to DTIC and interferon-gamma.

D Schadendorf1, M Worm, B M Czarnetzki.   

Abstract

The prognosis of patients with malignant melanoma and brain metastases is poor. Therapy of brain metastases is difficult and mostly unsuccessful, with brain metastases being the predominant factor which determines overall survival. We report here on a patient whose brain metastases responded to DTIC + INF-gamma. We present a short summary on the different effects on INF-alpha and INF-gamma and reach the conclusion that clinical trials which combine DTIC and INF-gamma should be performed. Based on this observation, combinations including INF-alpha are not necessarily comparable to modalities which include INF-gamma.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8410146     DOI: 10.1007/bf01324838

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  6 in total

Review 1.  The pharmacology and toxicology of the interferons: an overview.

Authors:  G J Mannering; L B Deloria
Journal:  Annu Rev Pharmacol Toxicol       Date:  1986       Impact factor: 13.820

2.  Brain metastases of malignant melanoma in interferon complete responders: clinical and radiological observations.

Authors:  O Merimsky; M Inbar; I Reider-Groswasser; S Chaitchik
Journal:  J Neurooncol       Date:  1992-02       Impact factor: 4.130

Review 3.  Therapy for cutaneous melanoma: an update.

Authors:  V C Ho; A J Sober
Journal:  J Am Acad Dermatol       Date:  1990-02       Impact factor: 11.527

4.  Treatment of advanced malignant melanoma with recombinant interferon alfa-2a in combination with DTIC: long-term follow-up of two phase II studies.

Authors:  P Hersey; G R McLeod; D B Thomson
Journal:  Br J Haematol       Date:  1991-10       Impact factor: 6.998

Review 5.  Role of interferons in the therapy of melanoma.

Authors:  G Castello; V Ruocco; R A Satriano; D Zarrilli
Journal:  Melanoma Res       Date:  1992 Jan-Feb       Impact factor: 3.599

6.  Comparison of two soft-agar methods for assaying chemosensitivity of human tumours in vitro: malignant melanomas.

Authors:  K M Tveit; L Endresen; H E Rugstad; O Fodstad; A Pihl
Journal:  Br J Cancer       Date:  1981-10       Impact factor: 7.640

  6 in total
  2 in total

1.  Management of cerebral metastases from malignant melanoma: results of a combined, simultaneous treatment with fotemustine and irradiation.

Authors:  J Ulrich; G Gademann; H Gollnick
Journal:  J Neurooncol       Date:  1999-06       Impact factor: 4.130

Review 2.  Targeting brain metastases in patients with melanoma.

Authors:  Dionysis Papadatos-Pastos; Aspasia Soultati; Mark Harries
Journal:  Biomed Res Int       Date:  2013-12-23       Impact factor: 3.411

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.